Pulse nav.journalClub 趋势探索问题研究者

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026隐私政策

首页探索 nav.journalClub 趋势

⌘+K

ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab | Synapse

April 15, 2026Open Access

ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab

Key Points

The research aims to understand the variability of ATNIVS biomarker profiles in patients treated with lecanemab.
Assessment of ATNIVS biomarker profiles
Evaluation in a real-world patient setting
Qualitative analysis of biomarker heterogeneity
Substantial variability in ATNIVS biomarker profiles found
Implications for personalized treatment approaches
Data highlights the complexity of patient responses to lecanemab

Abstract

We identified substantial heterogeneity in ATNIVS biomarker profiles among patients receiving lecanemab in a real-world setting.

Read Full Paperexternally

Like

Bookmark

Share

View Full Paper

Cite This Study

Kurihara et al. (Sat,) studied this question.

synapsesocial.com/papers/69df2a4be4eeef8a2a6af768 https://doi.org/https://doi.org/10.1016/j.tjpad.2026.100567

Like

Bookmark

Share

View Full Paper